NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Baker Hughes Company (NYSE: BKR) on behalf of Baker Hughes stockholders. Our investigation concerns whether Baker Hughes has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On February 25, 2021, Baker Hughes filed its annual report with the SEC. In the report, Baker Hughes revealed that, in December of 2020, the SEC had notified Baker Hughes of an investigation into the Company “related to its books and records and internal controls regarding sales of its products and services in projects impacted by U.S. sanctions.” Baker Hughes also revealed that it had also initiated an internal review “regarding internal controls and compliance related to U.S. sanctions requirements.”
On this news, Baker Hughes share prices fell by $0.25 to close at $24.48 on February 26, 2021. Over the next several trading days, the price dropped as low as $23.00 per share on March 4, 2021.
If you purchased or otherwise acquired Baker shares and suffered a loss, are a long term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at email@example.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.